Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 1992 Mar;118(3):195–200. doi: 10.1007/BF01410134

Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats

Matthias H Seelig 1, Martin R Berger 1,✉, Bernhard K Keppler 2
PMCID: PMC12201813  PMID: 1548284

Abstract

The antineoplastic activity of the ruthenium complexestrans-imidazolium[tetrachlorobisimidazoleruthenate(III)], HIm(RuIm2Cl4),trans-indazolium-[tetrachlorobis(1H-indazole)ruthenate(III,N 2)], HInd [RuInd2Cl4(N 2)], andtrans-indazolium[tetrachlorobis(2H-indazole)ruthenate(III,N 1)], HInd[RuInd2Cl4-(N1)] was assessed in acetoxymethylmethylnitrosamine-induced autochthonous colorectal carcinomas of Sprague-Dawley rats. The model is not sensitive to clinically established antineoplastic agents, including cisplatin. An exception is the combination therapy with 5-fluorouracil/leucovorin, which shows moderate activity against the tumour model. In contrast to this general trend, the new substances were all active against this tumour. HIm(RuIm2Cl4) was very effective at all dosages applied (7.5 mg/kg, 5.3 mg/kg, and 3.8 mg/kg), as indicated by percentage treated/control (T/C values of 23%, 34.5%, and 44%. Toxicity was considerable as shown by a body weight change of −30%, −19%, and −9%. Nevertheless, the medium dose seems to be the optimum in terms of mortality (0% vs 15% in the control group), whereas at the highest dose, mortality increased as a result of substance toxicity, and at the lowest dose mortality increased through tumor growth combined with substance toxicity.

HInd[RuInd2Cl4(N2)] showed high efficacy at the highest dosage of 13 mg/kg, reaching a T/C value of 27% combined with 0% mortality versus 15% in the control group. In equimolar dosages (10 mg/kg, 7.1 mg/kg and 5.1 mg/kg), the compound is not as active as HIm-(RuIm2Cl4), as indicated by T/C values of 50.2%, 45.7%, and 38.6%. HInd[RuInd2Cl4(N1)] was slightly but not significantly better than HInd[RuInd2Cl4(N2)] at a dosage of 7.1 mg/kg and is advantageous over combination therapy with 5-fluorouracil and leucovorin (20/20 mg/kg) in terms of efficacy (T/C=37.6% versus 44.7%) and mortality (6% versus 33.3%).

Key words: Ruthenium complexes; Acetoxymethylmethylnitrosamine-induced autochthonous colorectal carcinoma; Antitumour activity, 5-fluorouracil, leucovorin

References

  1. Abruzzese JL, Levin B (1989) Treatment of advanced colorectal cancer. Hematol Oncol Clin N Am 3:135–151 [PubMed] [Google Scholar]
  2. Arbuck SG (1989) Overview of trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer 63:1036–1046 [DOI] [PubMed] [Google Scholar]
  3. Berger MR, Bischoff H, Hermanek P, Schmähl D (1984) Biological characterisation and chemotherapy of autochthonous colorectal tumors in rats. In: Klein HO (ed) Advances in the chemotherapy of gastrointestinal cancer. Perimed-Fachbuch, Cologne pp 75–81 [Google Scholar]
  4. Berger MR, Bischoff H, Garzon FT, Schmähl D (1986) Autochthonous acetoxymethylmethylnitrosamine-induced colorectal cancer in rats: a useful tool in selecting new antineoplastic compounds? Hepatogastroenterology 33:227–234 [PubMed] [Google Scholar]
  5. Berger MR, Garzon FT, Keppler BK, Schmähl D (1989) Efficacy of new ruthenium complexes against chemically induced autochthonous colorectal carcinoma in rats. Anticancer Res 9:761–766 [PubMed] [Google Scholar]
  6. Berger MR, Galeano A, Seelig M, Keppler BK (1990) HInd (RuInd2Cl4)trans-indazolium-bis(indazole)tetrachlororuthenate(III) hemihydrate. Drugs Future 15:992–994 [Google Scholar]
  7. Clarke MJ (1980) Oncological implications of the chemistry of ruthenium. In: Sigel H (ed) Metal ions in biological systems, vol 11, Metal complexes an anticancer agents. Dekker, Basel, pp 231–283 [Google Scholar]
  8. Galeano, A, Petru E, Berger MR, Schmähl D (1990) Use of various cytotoxic regimens in the palliative treatment of colon cancer. Tumordiagn Ther 11:104–110 [Google Scholar]
  9. Garzon FT, Berger MR, Keppler BK, Schmähl D (1987) Comparative antitumor activity of ruthenium derivatives with 5′-deoxy-5-fluorouridine in chemically induced colorectal tumors in SD rats. Cancer Chemother Pharmacol 19:347–349 [DOI] [PubMed] [Google Scholar]
  10. Keller HJ, Keppler BK, Schmähl D (1982) Antitumor activity ofcis-dihalogenobis(1-phenyl-1,3-butanedionato)titanium(IV) compounds against Walker 256 carcinosarcoma. Arzneim-Forsch/Drug Res 32:806–807 [PubMed] [Google Scholar]
  11. Keller HJ, Keppler BK, Schmähl D (1983) Antitumor activity ofcis-dihalogenobis(1-phenyl-1,3-butanedionato)titanium(IV) compounds. J Cancer Res Clin Oncol 105:109–110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Keppler, BK, Schmähl D (1986) Preclinical evaluation of dichlorobis(1-phenylbutane-1,3-dionato)titanium(IV) and budotitane. Arzneim-Forsch/Drug Res 36:1822–1828 [PubMed] [Google Scholar]
  13. Keppler BK, Rupp W, Endres H, Niebl H, Balzer W (1987) Synthesis, molecular structure, and tumor-inhibiting properties of imidazolium-bis(imidazole)tetrachlororuthenate (III) and its methyl-substituted derivatives. Inorg Chem 26:4366–4370 [Google Scholar]
  14. Keppler BK, Henn M, Juhl UM, Berger MR, Niebl R, Wagner FE (1989) New ruthenium complexes for the treatment of cancer. Prog Clin Biochem Med 10:41–69 [Google Scholar]
  15. Keppler BK, Berger MR, Klenner T, Heim ME (1990) Metal complexes as antitumour agents. Adv Drug Res 19:243–310 [Google Scholar]
  16. Kruskal WH, Wallis WA (1952a) Use of ranks in one criterion variance analysis (I). J Am Stat Assoc 47:583–621 [Google Scholar]
  17. Kruskal WH, Wallis WA (1952b) Use of ranks in one criterion variance analysis (II). J Am Stat Assoc 48:907–911 [Google Scholar]
  18. Merz R, Wagner I, Habs M, Schmähl D, Amberger H, Bachmann U (1981) Endoscopic diagnosis of chemically induced autochthonous colonic tumors in rats. Hepatogastroenterology 28:53–57 [PubMed] [Google Scholar]
  19. Narisawa T, Wong CQ, Weissburger JH (1975) Evaluation of endoscopic examination of colon tumors in rats. Dig Dis 20:928–934 [DOI] [PubMed] [Google Scholar]
  20. Schweiger M, Gall FP (1986) Maligne Tumoren des Kolons. In: Gall FP, Hermanek P, Tonah J (eds) Chirugische Onkologie, Springer, Berlin Heidelberg New York, pp 495–519 [Google Scholar]
  21. Wiessler M (1975) Chemie der Nitrosamine: II. Synthese alphafunktioneller Dimethylnitrosamine. Tetrahedron Lett 30:2575–2578 [Google Scholar]
  22. Wolmark N, Fischer B, Rockette H, Redmond C, Wickerham L, Fischer E, Jones J, Glass A, Lerner H, Lawrence W, Prager D, Wexler H, Evans J, Cruz A, Dimitrov N, Jochimsen P (1988) Postoperative adjuvant chemotherapy or BCG for colon cancer. Results from NASBP protocol C-0.1 J Natl Cancer Inst 80:30 [DOI] [PubMed] [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES